Recent

% | $
Quotes you view appear here for quick access.

Prana Biotechnology Limited Message Board

kadaicher1 1036 posts  |  Last Activity: 8 hours ago Member since: Jan 23, 2004
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    One step closer to the Huntington's trial

    by kadaicher1 Jun 30, 2015 11:17 AM
    kadaicher1 kadaicher1 8 hours ago Flag

    Yes OPM, it was always going to be the HD trial first. They are still on track. They have a good cash position. I thought the Reach2HD trial demonstrated some good indicators. There was a shift in the Htt levels toward normal. Indications are the atrophy advantage is there as in AD. Exec Function was improved and in particular over early stage patients. With a HD trial underway it could even be a 10x before results. The position they are in now is the preference they indicated before the trials started. What could be bad about that.
    IMAGINE was just a tiny biomarker trial, and for such a small trial they now know they went for the wrong biomarker. AD is not over by any means. It is just not the lead program.
    Now there will be a movement disorder MPAC also available soon.

    Sentiment: Strong Buy

  • Reply to

    pbt.ax volume 34 shares???

    by gyoung28105 Jul 3, 2015 8:52 AM
    kadaicher1 kadaicher1 Jul 3, 2015 12:12 PM Flag

    GY it just means nobody wants to sell with the milestones coming up and there are no market makers on the ASX to drive volume. It could mean a coiling spring or have something to do with the Aus tax year ending a few days ago. You pick.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 3, 2015 11:29 AM Flag

    Gee, some of the planets most respected researchers with probably close to a combined 100years of experience in the field at the top level, or a mob of multi ID message board rats who are battling to string together two intelligent sentences. I believe I will go with the Profs.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 3, 2015 11:21 AM Flag

    He did put the focus on metals and metal homeostasis. Hard to single out PBT2 when Prana have about 1500 MPACs.
    He did say the next series of articles have a focus on AD, with discussions around both the mechanistic and therapeutic implications of altered metal ion homeostasis. Maybe PBT2 will get an honorable mention there.

    Sentiment: Strong Buy

  • Reply to

    Looks like MM painted last price AH's

    by jtsendence Jul 1, 2015 4:57 PM
    kadaicher1 kadaicher1 Jul 3, 2015 1:24 AM Flag

    More from the article posted below. He is focused on OTC BB stocks
    [More and more investors are winning the game nowadays despite all bashers that float through the Internet that has become part of the game. Floor traders of market makers often watch CNBC, news wires and bulletin boards in order to follow the market during trading session. OTC BB market makers (MMs) don't use fundamental and technical analysis. However, what they do realize is a lot of dumb money does use this newest nitch charting or TA (Technical Analysis) to run a stock either up or down. To the MMs this is like taking candy from a baby. Simply they will paint the tape and use whatever tactic to affect the charting bands. Thus the public and dumb money they will have eating out of their hands. Effectively the MMs can show a strong stock growing weak by manipulating the close price in order to generate selling volume, delaying trading time to manipulate trading activities, or even stalling the ask without honoring orders to hold a stock price.
    MMs follow a simple code of business when making a market in a stock especially an OTC BB. That is the level that stocks will seek that yields the most volume. Now this is very important because they make money on the volume buying at the bid and selling at the ask. In other words, by making the market they are buying low and selling high. Now smart money adheres to that rule, so do all the market makers. They could careless whether the stock is at $83 or at $0.23. All they care about is the action thus being able to sell stock at the offer (The high) and buy stock at the bid (The low). To increase their profitability, they make the spread as great as possible on as many shares as they can especially if the volume falls off.]

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 3, 2015 12:50 AM Flag

    Thanks for the in depth info and comparison. Very interesting. That is quite an expensive orphan drug at $259,000 per year. To make a profit it will need to be a blockbuster. My first post was a cut from a chart in 000s, so their loss is 738,555,000, with over 800m pumped into R&D last year.

    Sentiment: Strong Buy

  • Reply to

    Iron Chelation and ICH - CQ v. Deferiprone

    by interesting2me Jul 1, 2015 11:04 AM
    kadaicher1 kadaicher1 Jul 2, 2015 3:45 PM Flag

    Read the last to CEO letters in the last two annual report. It is actually very late, so there is some truth in that joke. Toxicology was finished last December but from what I have read they are now working on which Parkinsonian orphan to go with.

    Sentiment: Strong Buy

  • Great news for VRTX holders and patients. Earnings for the drug Orkambi at $259,000 per year, on the upper end of investor predictions, according to "The Street".
    VRTX total revenue is $580,415,000 last calendar year. Net loss (738,555)
    Market cap $31B
    If Prana were to reach HD NDA and earnings from a HD drug for cognition ran to $500m then the market cap expectation of $4B does not seem so excessive. Current PRAN market cap is $56m.

    Sentiment: Strong Buy

  • kadaicher1 kadaicher1 Jul 2, 2015 2:44 PM Flag

    Good to see you buying bio. Far from being a scam, in a sane world Prana would have 200 scientists on staff going after the diseases contributed to by metals imbalance. They could have a pipeline bigger than ISIS. Prana have not even raised the dose yet or tried any combinations of their MPACs. Below are just some of the conditions I know which feature metal imbalance and/or prions. They need to get this HD trial underway to further validate the platform IMO.
    Parkinson's disease.
    Progressive Supranuclear Palsy (PSP)
    Corticobasal Degeneration (CBD)
    Multiple System Atrophy (MSA)
    Vascular Parkinsonism
    Dementia with Lewy bodies (DLB)
    Multiple Sclerosis
    Huntington's disease
    Alzheimer's disease
    Mixed dementia
    Frontotemporal dementia
    Normal age related memory loss
    Age related macular degeneration
    Traumatic brain injury
    Glioblastoma
    Depression
    Amyloidosis
    Prostate cancer
    Other cancers
    Cancer prevention
    CJD
    Metal poisoning

    Sentiment: Strong Buy

  • Reply to

    Looks like MM painted last price AH's

    by jtsendence Jul 1, 2015 4:57 PM
    kadaicher1 kadaicher1 Jul 2, 2015 1:54 PM Flag

    If you read that entire article I posted, that was just part of it, it gives a really good insight into how the MM works. He can naked short to create liquidity and he also wants a profit. He controls prices all through the day when things are slow. Once he has shorted it down he needs to find a way to make investors cough up stock to cover. It sure sucks, but I am not sure it is sinister in any way. I guess the last thing he wants is to generate a buy signal to tech traders which could run the price up. You can observe as he walks it down he stops before taking it into the very oversold territory, then after a few days once the indicators have recovered he will walk it down again. Hopefully we have a few near in milestones which will stop those games. Particularly the partial hold removal.

    Sentiment: Strong Buy

  • Reply to

    Speculation

    by goutah3006 Jul 2, 2015 11:42 AM
    kadaicher1 kadaicher1 Jul 2, 2015 12:41 PM Flag

    Goutah, you are in denial. Prana is a HD drug developer right now. IF they make it to an NDA for HD, then market cap could rise to the $4B mark.
    Now the 2 year safety data is in, the only thing that matters is the removal of the partial hold. That is the direct path to the NDA. NOTHING ELSE MATTERS.

    The AD extension results mean next to nothing now we have the safety. Better sell your shares now if all depends on the IMAGINE extension. Prana have always said they will take PBT2 to market in HD. Nothing has changed.

    I agree great extension results would bring PBT2 for AD back into contention for the spotlight, but I think we will just get more of the same, maybe a little better, but still not enough to shift HD out of the front position. Sell, I may want them.

    All just my opinion.

    Sentiment: Strong Buy

  • Reply to

    Looks like MM painted last price AH's

    by jtsendence Jul 1, 2015 4:57 PM
    kadaicher1 kadaicher1 Jul 2, 2015 3:59 AM Flag

    They are licensed to use smoke and mirrors.

    Investopedia-DEFINITION of 'Market Maker' A broker-dealer firm that accepts the risk of holding a certain number of shares of a particular security in order to facilitate trading in that security.

    Check out "Market Maker Speaks Out: "Ways of a Market Maker"
    Just like investors, MM Hate to take a loss. So 9 times out of 10 he will now sell 2000 at 1.00 making him short 4000 but with an average .81. At this time he would love to see a seller at .75 so he can cover his short and make a few bucks.
    But instead the market keeps moving up. Now it is 1.00 to 1.25 and here comes the buyer again at 1.25. He doesn't want to lose the call so now he needs to sell 4,000 at 1.25 to keep his break even point above the bid. Now he is short 8,000. Market moves up to 1.25 bid 1.50 offer here comes the buyer now he feels he must sell 8000 here because "stocks don't go up forever".
    Now he is short 16,000. And so on and so on. If the stock keeps moving up, before he realizes it he could be short 50k or 100k shares (depending how big his bank is). _________________________
    Finally the market closes for the day and on paper he may look all right in that his "break even" price may be around the closing price. But now he has to figure out how to entice sellers so he can cover this short. It is important to note that if this happened to one MM it has probably happened to most all of them.
    Some ways MM's entice sellers; Run the stock up with a "tight spread" in a fast market, then "open" up the spread to slow down the buying interest. After it has "cooled off" for a little while lower the offer below the last trade right after a small piece trades on the offer then tighten the spread so that the sellers feel they can take a "quick profit" by "hitting the bid" on the tight spread.
    Once the selling starts the MM's will walk it down in the afternoon.
    Hopefully after doing this for several days, it will demoralize the buyers. The volume will dry up and

    Sentiment: Strong Buy

  • Reply to

    Looks like MM painted last price AH's

    by jtsendence Jul 1, 2015 4:57 PM
    kadaicher1 kadaicher1 Jul 1, 2015 5:13 PM Flag

    Guys, manipulation of small biotech prices has gone way past suspicious.

    Sentiment: Strong Buy

  • Reply to

    Who needs PBT2?

    by esoteric687 Jul 1, 2015 10:03 AM
    kadaicher1 kadaicher1 Jul 1, 2015 5:06 PM Flag

    There is a joke in there but I refuse to be tempted. Is there a nice sister:-)

    Sentiment: Strong Buy

  • Reply to

    Who needs PBT2?

    by esoteric687 Jul 1, 2015 10:03 AM
    kadaicher1 kadaicher1 Jul 1, 2015 3:25 PM Flag

    That's funny.
    I bet his mum wishes she sent him to a proper school where he could socialize.

    Sentiment: Strong Buy

  • Reply to

    Data Mining Math

    by copper725 Jul 1, 2015 3:03 PM
    kadaicher1 kadaicher1 Jul 1, 2015 3:21 PM Flag

    From the 400odd patients who participated in the Dimebon trial only about 100 enrolled for the extension trial. The 300 who elected not to participate in the new trial are not classified as dropouts.
    Like I said in the post you deleted, thick as two short planks.

    Sentiment: Strong Buy

  • Reply to

    Data Mining Math

    by copper725 Jul 1, 2015 3:03 PM
    kadaicher1 kadaicher1 Jul 1, 2015 3:10 PM Flag

    Moron, so you deleted my reply with your post to get rid of it. Everybody else understands it was two trials and you are trying to mislead.

    Sentiment: Strong Buy

  • Reply to

    Data Mining Math

    by copper725 Jul 1, 2015 2:41 PM
    kadaicher1 kadaicher1 Jul 1, 2015 3:02 PM Flag

    Thick as two short planks copper.
    They were two different trials. People who didn't enroll in a second trial cannot be called drop outs.
    Eg From the 400 patient Dimebon ph3, just 104 enrolled in the extension study. The 300 were not classed as dropouts.

    Sentiment: Strong Buy

  • Reply to

    Iron Chelation and ICH - CQ v. Deferiprone

    by interesting2me Jul 1, 2015 11:04 AM
    kadaicher1 kadaicher1 Jul 1, 2015 2:33 PM Flag

    Not only is it more than a chelator, it is more than an ionophore. I guess that is not so surprising considering it is also an antibiotic.
    "What might be responsible for the significant differences in biological activity of 8-OHQs? Because structure determines function, the non-chelating regions of each 8-OHQ likely confer unique properties that alter activity. Hydrophobicity alone may affect bioactivity as HQ-161, HQ-415, and CQ have partition constants (log P) of ∼1.4, ∼4.5, and ∼2.9, respectively. Differences in hydrophobic character could alter subcellular distribution among cytosol, membranes, and organelles, thus causing significant effects in 8-OHQ activity and toxicity rescue"
    "Inside the cell, 8-OHQs could affect metal distribution between different cellular compartments, or they might directly impact metalloprotein activity. Metals are exceptionally common, spatially regulated protein co-factors predicted to modulate the activities of over 40% of enzymes, with an estimated 80% of oxidoreductases predicted to require copper or iron (40). Numerous enzymes that function in respiration, amino acid metabolism, TCA cycle, kinase/phosphatase activity, nucleotide metabolism, fatty acid metabolism, and stress responses require copper or iron to function (41). These metals can facilitate the formation of protein structures, the ability of proteins to signal properly, and directly participate in catalytic functions. But metals are also in limiting abundance and are typically protein-bound (42).

    Within this incredible wealth of potential targets, a few particular chelating activities of 8-OHQs have been described. CQ alters cytochrome cooxidase, aconitase, alkaline phosphatase, malate dehydrogenase, and SOD1 activity in yeast (39). CQ modifies the activity of a mitochondrial protein (CLK-1) to promote longevity in nematodes and mice (43). 8-OHQs inhibit histone demethylases (44). And CQ and PBT2 extract metals from Aβ"

    Sentiment: Strong Buy

  • Reply to

    Who needs PBT2?

    by esoteric687 Jul 1, 2015 10:03 AM
    kadaicher1 kadaicher1 Jul 1, 2015 2:04 PM Flag

    Idiot,idiot basher. Our numbers are exactly the same. The difference is that when people completed the IMAGINE trial , they were given the opportunity to enter another trial which they had not signed up for at the start.
    You are trying to say 7 people who elected the get their life back instead of signing up for another trial were trial drop outs. That is false. They did not sign up for the second trial.
    In your usual manner you sneakily tried to add 6 patients as dropouts. That makes a big difference to percentages in such a small trial.
    Luckily probably only GY is thick enough to fall for that move.

    Sentiment: Strong Buy

PRAN
1.15+0.02(+1.77%)Jul 2 4:00 PMEDT